Catalent 'Is Starting To Move In The Right Direction,' Analyst Says, But Cautions Lack of Visibility for FY24
Portfolio Pulse from Vandana Singh
Catalent Inc (NYSE: CTLT) reported better-than-expected Q3 results with revenue of $1.04 billion and adjusted EBITDA of $105 million. The Biologics segment drove the top-line beat, but the company lowered its guidance for fiscal 2023. William Blair reiterated its Market Perform rating, citing limited upside and lack of visibility into fiscal 2024.
June 13, 2023 | 4:51 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Catalent's Q3 results exceeded expectations, but the company lowered its fiscal 2023 guidance. William Blair maintains a Market Perform rating due to limited upside and lack of visibility into fiscal 2024.
Catalent's better-than-expected Q3 results are a positive sign, but the lowered guidance for fiscal 2023 and lack of visibility into fiscal 2024 create uncertainty for investors. William Blair's Market Perform rating suggests a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100